Management Guideline for Non-typhoidal Salmonellosis in Children

Purpose
This guideline is to provide a standardised approach to the initial assessment and management of non-typhoidal salmonellosis in children.

Scope
This guideline provides information for Children’s Health Queensland staff caring for paediatric patients with suspected non-typhoidal salmonellosis infections.

Related documents

Procedures, Guidelines, Protocols
- CHQ-PROT-63105-1 Isolation table – Symptom / Disease Organism
- CHQ-PROC-01036 Antimicrobial: Prescribing and Management
- CHQ Antimicrobial restrictions list
- CHQ-GDL-01067 Paediatric Bone and Joint Infection Management
Guideline

Management guideline for Non-Typhoidal Salmonellosis (NTS) in children

Salmonella sp. present in stool, no bacteraemia

<table>
<thead>
<tr>
<th>Less than six (6) months of age</th>
<th>Treat all infants under 6 months with seven (7) days of antibiotics (oral therapy reasonable if child well) (See Footnote A)</th>
</tr>
</thead>
</table>
|                                 | If febrile or unwell:  
|                                 | - A blood culture +/- Cerebrospinal fluid (CSF) is required.  
|                                 | - Commence parenteral antibiotic therapy pending culture results. |

| More than six (6) months of age | If well despite diarrhoea: observe. No treatment required.  
|                                 | If unwell or febrile or localising signs present:  
|                                 |  
|                                 | - Blood culture +/- CSF and consider empirical parenteral antibiotics particularly if less than 12 months of age.  
|                                 | - If blood culture is negative at 48 hours and clinically well, switch to oral antibiotics to complete seven (7) days. |

| Prolonged carriage | Repeated stool testing is not recommended.  
|                    | There is no evidence to support treatment of prolonged carriage. |

| Persistent diarrhoea | Consult Paediatric Infectious Diseases Specialist. |

Salmonella Bacteraemia (uncomplicated) (See Footnote B)

<table>
<thead>
<tr>
<th>Less than 3 months of age:</th>
<th>Ten days parenteral antibiotics. CSF analysis in all cases.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 to 12 months of age:</td>
<td>Seven days parenteral antibiotics. CSF analysis if clinically indicated.</td>
</tr>
<tr>
<td>More than 12 months of age:</td>
<td>Seven days antibiotics (sequential parenteral / oral therapy reasonable if child well).</td>
</tr>
</tbody>
</table>

Complicated infection

Meningitis

- Intravenous Cefotaxime or Ceftriaxone for 4 to 6 weeks.  
- Consider repeat lumbar puncture after 48 to 72 hours of therapy to ensure CSF sterility.  
- If persistent growth in CSF, add Ciprofloxacin (if susceptible) to Cefotaxime or Ceftriaxone for duration of therapy.

Osteomyelitis

- Four to six weeks antibiotics (the required parenteral duration is not established, suggest minimum 2 to 4 weeks parenteral antibiotics).
Selection of antibiotics (See Footnote C)
Choice of antibiotics depends on antibiotic sensitivities of Salmonella sp.

Recommended parenteral empiric therapy while awaiting sensitivities is:
- Cefotaxime IV 50 mg/kg/dose (maximum 2 g/dose) 6-hourly.
  or
- Ceftriaxone IV 100 mg/kg 24 hourly (maximum 4 g/day).

Recommended empiric oral therapy:
- Oral Azithromycin: 20 mg/kg (maximum 1 g) for first dose then 10 mg/kg (maximum 500 mg) once daily for further 6 days.

Alternative oral options:
- Oral Amoxicillin 30 mg/kg/dose (maximum 1 g/dose) three times daily.
  or
- Oral Trimethoprim-sulfamethoxazole 4 mg/kg/dose (maximum 160 mg trimethoprim component per dose) twice daily.

Targeted antibiotic therapy is based on antibiotic susceptibilities of Salmonella species.

A. There is very limited evidence to guide treatment recommendations for NTS gastroenteritis in young infants (less than six (6) months of age). Due to the increased risk for invasive disease and severe sequelae of invasive infection, we recommend treating all infants in this age group although risk of extra-intestinal dissemination needs to be balanced against the well-established risk of prolonged excretion.

B. Current literature suggests 7 to 10 days of antibiotics is sufficient for most age groups. Due to the increased risk for complications following bacteraemia, it is recommended a CSF analysis is performed in all infants under three (3) months.

C. Regular review of resistance patterns recommended to guide empiric antibiotic therapy. Recommended empirical oral therapy is Amoxicillin, Trimethoprim-sulfamethoxazole or Azithromycin. Azithromycin should be used particularly if there are concerns about resistance (e.g. returned travellers). Some caution is needed if using Trimethoprim-sulfamethoxazole in infants less than two (2) months (risk of kernicterus) and in using Azithromycin in infants less than one (1) month (risk of hypertrophic pyloric stenosis).

D. Salmonella is a notifiable disease. Contact Public Health.
Consultation

Key stakeholders who reviewed this version:
- Director, Infection Management and Prevention services, Immunology and Rheumatology (CHQ)
- Infection Specialists, Infection Management and Prevention service (CHQ)
- Consultant Paediatrician, General Paediatrics (CHQ)
- Clinical Pharmacist Lead - Antimicrobial Stewardship Pharmacist (CHQ)

References and suggested reading

1. Therapeutic Guidelines: Antibiotic 2020 Therapeutic Guidelines Ltd. Melbourne

Guideline revision and approval history

<table>
<thead>
<tr>
<th>Version No.</th>
<th>Modified by</th>
<th>Amendments authorised by</th>
<th>Approved by</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Infectious Diseases Consultant, Infection Management and Prevention services</td>
<td>Antimicrobial Stewardship Team</td>
<td>EDMS, Chair Medicines Advisory Committee</td>
</tr>
<tr>
<td>2.0</td>
<td>Infectious Diseases Consultant, Infection Management and Prevention services</td>
<td>Antimicrobial Stewardship Team</td>
<td>EDMS, Chair Medicines Advisory Committee</td>
</tr>
<tr>
<td>3.0</td>
<td>Infectious Diseases Consultant, Infection Management and Prevention Service (IMPS)</td>
<td>Medicines Advisory Committee (CHQ)</td>
<td>Executive Director Clinical Service (QCH)</td>
</tr>
<tr>
<td>4.0</td>
<td>Infectious Diseases Consultants (IMPS), Pharmacist Advanced – Antimicrobial Stewardship</td>
<td>Medicines Advisory Committee (CHQ)</td>
<td>Executive Director Clinical Service (QCH)</td>
</tr>
<tr>
<td>5.0</td>
<td>Infectious Diseases Consultants (IMPS), Clinical Pharmacist Lead – Antimicrobial Stewardship</td>
<td>Director IMPS</td>
<td>Divisional Director Medicine</td>
</tr>
</tbody>
</table>

Keywords
Non-typhoidal Salmonellosis, meningitis, osteomyelitis, antibiotics, children, salmonella bacteraemia, cefotaxime, ceftriaxone, amoxicillin, azithromycin, trimethoprim-sulfamethoxazole, 63001

Accreditation references